Shigellosis
- PMID: 15880088
Shigellosis
Abstract
Shigellosis is a global human health problem. Four species of Shigella i.e. S. dysenteriae, S. flexneri, S. boydii and S. sonnei are able to cause the disease. These species are subdivided into serotypes on the basis of O-specific polysaccharide of the LPS. Shigella dysenteriae type 1 produces severe disease and may be associated with life-threatening complications. The symptoms of shigellosis include diarrhoea and/or dysentery with frequent mucoid bloody stools, abdominal cramps and tenesmus. Shigella spp. cause dysentery by invading the colonic mucosa. Shigella bacteria multiply within colonic epithelial cells, cause cell death and spread laterally to infect and kill adjacent epithelial cells, causing mucosal ulceration, inflammation and bleeding. Transmission usually occurs via contaminated food and water or through person-to-person contact. Laboratory diagnosis is made by culturing the stool samples using selective/differential agar media. Shigella spp. are highly fragile organism and considerable care must be exercised in collecting faecal specimens, transporting them to the laboratories and in using appropriate media for isolation. Antimicrobial agents are the mainstay of therapy of all cases of shigellosis. Due to the global emergence of drug resistance, the choice of antimicrobial agents for treating shigellosis is limited. Although single dose of norfloxacin and ciprofloxacin has been shown to be effective, they are currently less effective against S. dysenteriae type 1 infection. Newer quinolones, cephalosporin derivatives, and azithromycin are the drug of choice. However, fluoroquinolone-resistant S. dysenteriae type 1 infection have been reported. Currently, no vaccines against Shigella infection exist. Both live and subunit parenteral vaccine candidates are under development. Because immunity to Shigella is serotype-specific, the priority is to develop vaccine against S. dysenteriae type 1 and S. flexneri type 2a. Shigella species are important pathogens responsible for diarrhoeal diseases and dysentery occurring all over the world. The morbidity and mortality due to shigellosis are especially high among children in developing countries. A recent review of literature (Kotloff et al.,1999) concluded that, of the estimated 165 million cases of Shigella diarrhoea that occur annually, 99% occur in developing countries, and in developing countries 69% of episodes occur in children under five years of age. Moreover, of the ca.1.1 million deaths attributed to Shigella infections in developing countries, 60% of deaths occur in the under-five age group. Travellers from developed to developing regions and soldiers serving under field conditions are also at an increased risk to develop shigellosis.
Similar articles
-
Shigellosis : challenges & management issues.Indian J Med Res. 2004 Nov;120(5):454-62. Indian J Med Res. 2004. PMID: 15591629 Review.
-
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.Bull World Health Organ. 1999;77(8):651-66. Bull World Health Organ. 1999. PMID: 10516787 Free PMC article.
-
Shigella isolates of Nepal: changes in the incidence of shigella subgroups and trends of antimicrobial susceptibility pattern.Kathmandu Univ Med J (KUMJ). 2007 Jan-Mar;5(1):32-7. Kathmandu Univ Med J (KUMJ). 2007. PMID: 18603983
-
Frequency of isolation of various subtypes and antimicrobial resistance of Shigella from urban slums of Karachi, Pakistan.Int J Infect Dis. 2009 Nov;13(6):668-72. doi: 10.1016/j.ijid.2008.10.005. Epub 2009 Jan 8. Int J Infect Dis. 2009. PMID: 19135399
-
Shigellosis: the current status of vaccine development.Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Curr Opin Infect Dis. 2008. PMID: 18448978 Review.
Cited by
-
Effects of inactivated Lactobacillus rhamnosus on growth performance, serum indicators, and colonic microbiota and metabolism of weaned piglets.BMC Vet Res. 2024 Sep 20;20(1):422. doi: 10.1186/s12917-024-04133-5. BMC Vet Res. 2024. PMID: 39304851
-
Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer Patients.Int J Mol Sci. 2024 Jul 23;25(15):8026. doi: 10.3390/ijms25158026. Int J Mol Sci. 2024. PMID: 39125593 Free PMC article.
-
Investigation of the vaccine potential of an in silico designed FepA peptide vaccine against Shigella flexneri in mice model.Vaccine X. 2024 May 8;18:100493. doi: 10.1016/j.jvacx.2024.100493. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38812954 Free PMC article.
-
Epidemiological analysis and prevention strategies in response to a shigellosis cluster outbreak: a retrospective case series in an alternative school in the Republic of Korea, 2023.Osong Public Health Res Perspect. 2024 Feb;15(1):68-76. doi: 10.24171/j.phrp.2023.0298. Epub 2024 Feb 7. Osong Public Health Res Perspect. 2024. PMID: 38481051 Free PMC article.
-
Occurrences and implications of pathogenic and antibiotic-resistant bacteria in different stages of drinking water treatment plants and distribution systems.Heliyon. 2024 Feb 16;10(4):e26380. doi: 10.1016/j.heliyon.2024.e26380. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38434035 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous